View : 137 Download: 0
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women with Hormone Receptor-Positive Breast Cancer after Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
- Title
- Adding Ovarian Suppression to Tamoxifen for Premenopausal Women with Hormone Receptor-Positive Breast Cancer after Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
- Authors
- Eunhwa; Sung Yong; Min Hyuk; Lee Su; Lim; Woosung; Seonok; Hee Jeong; Baek; Soo Yeon; Noh; Woo Chul; Ahn; Sei-Hyun; Kim; Hyun-Ah; Ryu; Jai Min; Seung Il; Lee; Eun-Gyeong; Im; Seock-Ah; Jung; Yongsik; Park; Min Ho; Kyong Hwa; Kang; Su Hwan; Jeong; Joon
- Ewha Authors
- 임우성
- SCOPUS Author ID
- 임우성
- Issue Date
- 2023
- Journal Title
- Journal of Clinical Oncology
- ISSN
- 0732-183X
- Citation
- Journal of Clinical Oncology vol. 41, no. 31, pp. 4864 - 4871
- Publisher
- Lippincott Williams and Wilkins
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- PURPOSETo determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy (ASTRRA) trial.PATIENTS AND METHODSThis study is a post-trial follow-up of the ASTRRA trial, involving 1,483 premenopausal women younger than 45 years treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy for estrogen receptor-positive breast cancer. Patients were randomly assigned in a 1:1 ratio to complete 5 years of tamoxifen (TAM) alone (TAM-only) or 5 years of TAM with ovarian function suppression (OFS) for 2 years (TAM + OFS). The primary end point was disease-free survival (DFS), and the secondary end point was overall survival (OS).RESULTSAt 106.4 months of median follow-up, there was a continuous significant reduction in the DFS event rate in the TAM + OFS group. The 8-year DFS rate was 85.4% in the TAM + OFS group and 80.2% in the TAM-only group (hazard ratio [HR], 0.67; 95% CI, 0.51 to 0.87). There were no significant differences in OS between the two groups. The OS rate was 96.5% in the TAM + OFS group and 95.3% in the TAM-only group (HR, 0.78; 95% CI, 0.49 to 1.25).CONCLUSIONAdding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy. © American Society of Clinical Oncology.
- DOI
- 10.1200/JCO.23.00557
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML